Key facts
- It has raised $95.3M; the latest was Later Stage VC ($8.2M) in Dec 2024.
- Notable investors include Korea Development Bank, Premier Partners, Korea Venture Investment, AJU IB Investment, Devsisters Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Karis Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Karis Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Karis Bio
Developer of cell therapy designed to treat cardiovascular disease. The company develops cell-based therapy for treating patients with cardiovascular diseases using patented clinically applicable Induced pluripotent stem cells (iPSC) generation and endothelial cell differentiation technology, enabling patients to recover from cardiovascular disease.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2020
- Employees
- 31
- Website
- karisbio.com/
- Ownership
- Privately Held (backing)
Karis Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Karis Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Karis Bio in its N-PORT filings yet. We sweep new filings monthly.